Brixton Metals Corporation press release

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CLVT, GATO and CABA

2022-03-08

TSXV - TSX Venture Exchange · Copper · Gold · Silver · Molybdenum · Lead · Zinc · Antimony · Tellurium · Arsenic · Barium · Cadmium · Fluorite · Cobalt · Nickel · Canada

NEW YORK, NY / ACCESSWIRE / March 8, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Clarivate Plc (NYSE:CLVT)

Investors Affected : February 26, 2021 - December 27, 2021

A class action has commenced on behalf of certain shareholders in Clarivate Plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Clarivate maintained defective disclosure controls and procedures as a result of a material weakness in its internal control over financial reporting; (ii) the foregoing material weakness was not limited to how the Company accounted for warrants; (iii) as a result, Clarivate failed to properly account for an equity plan included in its acquisition of CPA Global, a global leader in Intellectual Property software and tech-enabled services; (iv) accordingly, the Company was reasonably likely to restate one or more of its previously issued financial statements following its acquisition of CPA Global; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/clarivate-plc-loss-submission-form/?id=24440&from=1

Gatos Silver, Inc. (NYSE:GATO)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020 and January 25, 2022, inclusive.

A class action has commenced on behalf of certain shareholders in Gatos Silver, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos's primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/gatos-silver-inc-loss-submission-form/?id=24440&from=1

Cabaletta Bio, Inc. (NASDAQ:CABA)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.

A class action has commenced on behalf of certain shareholders in Cabaletta Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/cabaletta-bio-inc-loss-submission-form/?id=24440&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (212) 537-9430 Fax: (833) 862-7770

SOURCE : The Gross Law Firm

View source version on accesswire.com: https://www.accesswire.com/692124/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-CLVT-GATO-and-CABA